+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-obesity Prescription Drugs Market Research Report by Drug Class, Age Group, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4904662
  • Report
  • April 2022
  • Region: Global
  • 202 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • 7TM Pharma A/S
  • Arrowhead Pharmaceuticals
  • Bristol-Myers Squibb Co
  • Eisai Co., Ltd
  • GlaxoSmithKline PLC
  • Norgine BV
The Global Anti-obesity Prescription Drugs Market size was estimated at USD 5,342.71 million in 2021, USD 5,761.56 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.01% to reach USD 8,486.13 million by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Anti-obesity Prescription Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the market was studied across Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate.
  • Based on Age Group, the market was studied across Adult and Pediatric.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Anti-obesity Prescription Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-obesity Prescription Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-obesity Prescription Drugs Market, including 7TM Pharma A/S, Akrimax Pharmaceuticals Inc, Alizyme PLC, Arena Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co, C.H. Boehringer Sohn AG & Ko. KG, Cadila Healthcare Limited, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Norgine BV, Novo Nordisk A/s, Orexigen Therapeutics, Inc, Pfizer Inc,, Rhythm Pharmaceuticals, Inc., Shionogi USA Inc, Takeda Pharmaceutical Company Limited, Vivus Inc, and Zafgen Inc.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Anti-obesity Prescription Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-obesity Prescription Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-obesity Prescription Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Anti-obesity Prescription Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Anti-obesity Prescription Drugs Market?
6. What is the market share of the leading vendors in the Global Anti-obesity Prescription Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Anti-obesity Prescription Drugs Market?
Frequently Asked Questions about the Global Anti-obesity Prescription Drugs Market

What is the estimated value of the Global Anti-obesity Prescription Drugs Market?

The Global Anti-obesity Prescription Drugs Market was estimated to be valued at $5342.7 Million in 2021.

What is the growth rate of the Global Anti-obesity Prescription Drugs Market?

The growth rate of the Global Anti-obesity Prescription Drugs Market is 8.0%, with an estimated value of $8486.1 Million by 2027.

What is the forecasted size of the Global Anti-obesity Prescription Drugs Market?

The Global Anti-obesity Prescription Drugs Market is estimated to be worth $8486.1 Million by 2027.

Who are the key companies in the Global Anti-obesity Prescription Drugs Market?

Key companies in the Global Anti-obesity Prescription Drugs Market include 7TM Pharma A/S, Akrimax Pharmaceuticals Inc, Alizyme PLC, Arena Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, Bayer AG, Bristol, Myers Squibb Co and Cadila Healthcare Limited.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 7TM Pharma A/S
  • Arrowhead Pharmaceuticals
  • Bristol-Myers Squibb Co
  • Eisai Co., Ltd
  • GlaxoSmithKline PLC
  • Norgine BV

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of obesity and related chronic diseases
5.1.1.2. Growing unhealthy and sedentary lifestyle
5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
5.1.2. Restraints
5.1.2.1. Side effect related to anti-obesity drugs
5.1.3. Opportunities
5.1.3.1. Introduction of novel anti-obesity drugs
5.1.4. Challenges
5.1.4.1. Availability of alternative treatment options
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Anti-obesity Prescription Drugs Market, by Drug Class
6.1. Introduction
6.2. Bupropion and Naltrexone
6.3. Liraglutide
6.4. Lorcaserin
6.5. Orlistat
6.6. Phentermine and Topiramate
7. Anti-obesity Prescription Drugs Market, by Age Group
7.1. Introduction
7.2. Adult
7.3. Pediatric
8. Anti-obesity Prescription Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Americas Anti-obesity Prescription Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Anti-obesity Prescription Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 7TM Pharma A/S
13.2. Akrimax Pharmaceuticals Inc
13.3. Alizyme PLC
13.4. Arena Pharmaceuticals, Inc
13.5. Arrowhead Pharmaceuticals
13.6. Bayer AG
13.7. Bristol-Myers Squibb Co
13.8. C.H. Boehringer Sohn AG & Ko. KG
13.9. Cadila Healthcare Limited
13.10. Currax Pharmaceuticals LLC
13.11. Eisai Co., Ltd
13.12. F. Hoffmann-La Roche AG
13.13. GlaxoSmithKline PLC
13.14. Merck & Co.
13.15. Norgine BV
13.16. Novo Nordisk A/s
13.17. Orexigen Therapeutics, Inc
13.18. Pfizer Inc,
13.19. Rhythm Pharmaceuticals, Inc.
13.20. Shionogi USA Inc
13.21. Takeda Pharmaceutical Company Limited
13.22. Vivus Inc
13.23. Zafgen Inc
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: DYNAMICS
FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2027
FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, 2019-2027 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, 2019-2027 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, 2019-2027 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, 2019-2027 (USD MILLION)
FIGURE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, 2019-2027 (USD MILLION)
FIGURE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2021 VS 2027 (%)
FIGURE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2021 VS 2027 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2027
FIGURE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, 2019-2027 (USD MILLION)
FIGURE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, 2019-2027 (USD MILLION)
FIGURE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2027
FIGURE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2019-2027 (USD MILLION)
FIGURE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2019-2027 (USD MILLION)
FIGURE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 31. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 32. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 33. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 34. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 35. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 36. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 37. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 38. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 39. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 40. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 41. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 42. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 43. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 44. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 45. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 46. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 47. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 48. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 49. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 50. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 51. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 52. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 53. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 54. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 55. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 56. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 57. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 58. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 59. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 60. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 63. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2019-2027 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY REGION, 2019-2027 (USD MILLION)
TABLE 5. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION AND NALTREXONE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2019-2027 (USD MILLION)
TABLE 10. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY REGION, 2019-2027 (USD MILLION)
TABLE 15. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 16. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY STATE, 2019-2027 (USD MILLION)
TABLE 17. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2019-2027 (USD MILLION)
TABLE 20. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 21. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY STATE, 2019-2027 (USD MILLION)
TABLE 22. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY REGION, 2019-2027 (USD MILLION)
TABLE 25. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 26. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY STATE, 2019-2027 (USD MILLION)
TABLE 27. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE AND TOPIRAMATE, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2019-2027 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY REGION, 2019-2027 (USD MILLION)
TABLE 31. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 32. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY STATE, 2019-2027 (USD MILLION)
TABLE 33. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2019-2027 (USD MILLION)
TABLE 36. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 37. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY STATE, 2019-2027 (USD MILLION)
TABLE 38. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2019-2027 (USD MILLION)
TABLE 42. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 43. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 44. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2019-2027 (USD MILLION)
TABLE 47. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 48. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 49. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2019-2027 (USD MILLION)
TABLE 52. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 53. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY STATE, 2019-2027 (USD MILLION)
TABLE 54. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2019-2027 (USD MILLION)
TABLE 56. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 57. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 58. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 59. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 60. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 61. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 63. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 64. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 65. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 66. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 67. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 68. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 69. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 70. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 71. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 72. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 73. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 75. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 76. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 77. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 78. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 79. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 80. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 81. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 82. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 83. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 84. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 85. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 86. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SCORES
TABLE 87. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: BUSINESS STRATEGY
TABLE 88. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: PRODUCT SATISFACTION
TABLE 89. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: RANKING
TABLE 90. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 91. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: MERGER & ACQUISITION
TABLE 92. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 93. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 94. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: INVESTMENT & FUNDING
TABLE 95. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 96. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • 7TM Pharma A/S
  • Akrimax Pharmaceuticals Inc
  • Alizyme PLC
  • Arena Pharmaceuticals, Inc
  • Arrowhead Pharmaceuticals
  • Bayer AG
  • Bristol-Myers Squibb Co
  • C.H. Boehringer Sohn AG & Ko. KG
  • Cadila Healthcare Limited
  • Currax Pharmaceuticals LLC
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co.
  • Norgine BV
  • Novo Nordisk A/s
  • Orexigen Therapeutics, Inc
  • Pfizer Inc,
  • Rhythm Pharmaceuticals, Inc.
  • Shionogi USA Inc
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc
  • Zafgen Inc
Note: Product cover images may vary from those shown

Loading
LOADING...